GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evogene Ltd (XTAE:EVGN) » Definitions » Cyclically Adjusted Revenue per Share

Evogene (XTAE:EVGN) Cyclically Adjusted Revenue per Share : ₪0.81 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Evogene Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Evogene's adjusted revenue per share for the three months ended in Dec. 2023 was ₪0.043. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₪0.81 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Evogene's average Cyclically Adjusted Revenue Growth Rate was -30.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-01), Evogene's current stock price is ₪2.502. Evogene's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was ₪0.81. Evogene's Cyclically Adjusted PS Ratio of today is 3.09.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Evogene was 4.50. The lowest was 1.66. And the median was 2.45.


Evogene Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Evogene's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evogene Cyclically Adjusted Revenue per Share Chart

Evogene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 1.43 1.17 0.81

Evogene Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.17 1.07 0.98 0.91 0.81

Competitive Comparison of Evogene's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Evogene's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evogene's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evogene's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Evogene's Cyclically Adjusted PS Ratio falls into.



Evogene Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Evogene's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.043/129.4194*129.4194
=0.043

Current CPI (Dec. 2023) = 129.4194.

Evogene Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.579 99.695 0.752
201406 0.586 100.560 0.754
201409 0.481 100.428 0.620
201412 0.528 99.070 0.690
201503 0.385 99.621 0.500
201506 0.401 100.684 0.515
201509 0.475 100.392 0.612
201512 0.369 99.792 0.479
201603 0.290 100.470 0.374
201606 0.272 101.688 0.346
201609 0.224 101.861 0.285
201612 0.172 101.863 0.219
201703 0.106 102.862 0.133
201706 0.171 103.349 0.214
201709 0.108 104.136 0.134
201712 0.106 104.011 0.132
201803 0.053 105.290 0.065
201806 0.055 106.317 0.067
201809 0.053 106.507 0.064
201812 0.092 105.998 0.112
201903 0.050 107.251 0.060
201906 0.028 108.070 0.034
201909 0.014 108.329 0.017
201912 0.017 108.420 0.020
202003 0.011 108.902 0.013
202006 0.043 108.767 0.051
202009 0.044 109.815 0.052
202012 0.038 109.897 0.045
202103 0.032 111.754 0.037
202106 0.012 114.631 0.014
202109 0.014 115.734 0.016
202112 0.028 117.630 0.031
202203 0.021 121.301 0.022
202206 0.028 125.017 0.029
202209 0.042 125.227 0.043
202212 0.060 125.222 0.062
202303 0.058 127.348 0.059
202306 0.059 128.729 0.059
202309 0.288 129.860 0.287
202312 0.043 129.419 0.043

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Evogene  (XTAE:EVGN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Evogene's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2.502/0.81
=3.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Evogene was 4.50. The lowest was 1.66. And the median was 2.45.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Evogene Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Evogene's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Evogene (XTAE:EVGN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evogene Ltd (XTAE:EVGN) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
13 Gad Feinstein Street, Park Rehovot, P.O. Box 4173, Ness Ziona, Rehovot, ISR, 7414002
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment.